In Brookes et al. (2018)’s study, the authors recruited patients with previous ischemic stroke or transient ischemic attack and found that these patients treated with sodium valproate, a non-specific inhibitor of HDAC9, had a lower risk of recurrent stroke. This evidence concerns the gene HDAC9 and Stroke.